RESUMEN
HLA-DPB1*05:01:21 differs from HLA-DPB1*05:01:01:01 by one nucleotide in exon 3.
Asunto(s)
Cadenas beta de HLA-DP , Nucleótidos , Humanos , Alelos , Secuencia de Bases , ChinaRESUMEN
HLA-DPA1*02:117 differs from HLA-DPA1*02:02:02:01 by one nucleotide in exon 2.
Asunto(s)
Cadenas alfa de HLA-DP , Nucleótidos , Humanos , Alelos , Cadenas alfa de HLA-DP/genética , China , Análisis de Secuencia de ADNRESUMEN
HLA-C*17:69 differs from HLA-C*17:01:01:02 by one nucleotide in exon 4.
Asunto(s)
Antígenos HLA-C , Nucleótidos , Humanos , Antígenos HLA-C/genética , Alelos , Secuencia de Bases , China , Análisis de Secuencia de ADNRESUMEN
HLA-C*03:651 differs from HLA-C*03:03:01:01 by one nucleotide in exon 4.
Asunto(s)
Antígenos HLA-C , Nucleótidos , Humanos , Antígenos HLA-C/genética , Alelos , Secuencia de Bases , China , Análisis de Secuencia de ADNRESUMEN
HLA-B*40:555 differs from HLA-B*40:01:02:01 by one nucleotide in exon 3.
Asunto(s)
Antígenos HLA-B , Nucleótidos , Humanos , Alelos , Análisis de Secuencia de ADN , Antígenos HLA-B/genética , ChinaRESUMEN
HLA-B*40:550 differs from HLA-B*40:01:02:01 by one nucleotide in exon 1.
Asunto(s)
Exones , Antígeno HLA-B40 , Prueba de Histocompatibilidad , Humanos , Alelos , Secuencia de Bases , Codón , Pueblos del Este de Asia , Antígeno HLA-B40/genética , Alineación de Secuencia , Análisis de Secuencia de ADN/métodosRESUMEN
HLA-DPB1*1553:01 differs from HLA-DPB1*09:01:01:01 by one nucleotide in exon 3.
Asunto(s)
Exones , Cadenas beta de HLA-DP , Prueba de Histocompatibilidad , Humanos , Alelos , Secuencia de Bases , Codón , Pueblos del Este de Asia , Cadenas beta de HLA-DP/genética , Alineación de Secuencia , Análisis de Secuencia de ADN/métodos , Donantes de TejidosRESUMEN
HLA-B*15:659 differs from HLA-B*15:02:01:01 by one nucleotide in exon 2.
Asunto(s)
Alelos , Pueblo Asiatico , Secuencia de Bases , Exones , Prueba de Histocompatibilidad , Análisis de Secuencia de ADN , Humanos , Pueblo Asiatico/genética , Análisis de Secuencia de ADN/métodos , Antígeno HLA-B15/genética , Antígeno HLA-B15/inmunología , Alineación de Secuencia , Codón , Donantes de Tejidos , Pueblos del Este de AsiaRESUMEN
Purpose: The objective of this study was to provide theoretically feasible strategies by understanding the relationship between the immune microenvironment and the diagnosis and prognosis of AML patients. To this end, we built a ceRNA network with lncRNAs as the core and analyzed the related lncRNAs in the immune microenvironment by bioinformatics analysis. Methods: AML transcriptome expression data and immune-related gene sets were obtained from TCGA and ImmPort. Utilizing Pearson correlation analysis, differentially expressed immune-related lncRNAs were identified. Then, the LASSO-Cox regression analysis was performed to generate a risk signature consisting immune-related lncRNAs. Accuracy of signature in predicting patient survival was evaluated using univariate and multivariate analysis. Next, GO and KEGG gene enrichment and ssGSEA were carried out for pathway enrichment analysis of 183 differentially expressed genes, followed by drug sensitivity and immune infiltration analysis with pRRophetic and CIBERSORT, respectively. Cytoscape was used to construct the ceRNA network for these lncRNAs. Results: 816 common lncRNAs were selected to acquire the components related to prognosis. The final risk signature established by multivariate Cox and stepwise regression analysis contained 12 lncRNAs engaged in tumor apoptotic and metastatic processes: LINC02595, HCP5, AC020934.2, AC008770.3, LINC01770, AC092718.4, AL589863.1, AC131097.4, AC012368.1, C1RL-AS1, STARD4-AS1, and AC243960.1. Based on this predictive model, high-risk patients exhibited lower overall survival rates than low-risk patients. Signature lncRNAs showed significant correlation with tumor-infiltrating immune cells. In addition, significant differences in PD-1/PD-L1 expression and bleomycin/paclitaxel sensitivity were observed between risk groups. Conclusion: LncRNAs related to immune microenvironment were prospective prognostic and therapeutic options for AML.